Court Blocks Mail Access to Mifepristone

A U.S. appeals court has temporarily blocked a federal rule allowing mifepristone, an abortion drug, to be distributed through the mail. This decision significantly restricts access, especially in states with abortion bans. The 5th Circuit Court of Appeals says Louisiana is likely to succeed in its legal challenge.

The United States appeals court has issued a temporary injunction against a federal provision allowing the distribution of mifepristone via mail. This ruling markedly limits access to the abortion medication across the country, particularly impacting states enforcing bans on abortion.

The decision was made by a panel of the 5th U.S. Circuit Court of Appeals based in New Orleans, who noted that the state of Louisiana stands a strong chance of succeeding in its legal contest against the 2023 rule implemented by the administration of Democratic former President Joe Biden.

This interim ruling marks a significant development in ongoing litigation targeting both the original approval of mifepristone in 2000 and subsequent deregulations such as the 2023 adjustment which eliminated the requirement for in-person dispensing of the drug.